马萨诸塞州贝德福德 - 专注于开发眼科疾病治疗方案的生物制药公司Ocular Therapeutix, Inc. (NASDAQ: OCUL)宣布任命Namrata Saroj博士为首席业务官。Saroj博士在眼科药物开发领域拥有超过20年的经验，自2024年2月起一直担任公司的开发战略顾问，现将全职加入领导团队。 Saroj博士的职业生涯包括对主要FDA批准的眼科药物（如LUCENTIS®和EY ...

Lucentis' main patents are not due to expire in Europe until next year, but Samsung Bioepis and Biogen are now poised to roll out the drug as soon the intellectual property on the drug lapses.

The US FDA has approved a new biosimilar of Roche and Novartis' blockbuster ophthalmology therapy Lucentis – Coherus BioSciences' Cimerli – which its developer claims is the first to be fully ...

但「湿性」患者则可靠注射「血管内皮生长因子抑制剂」（Anti-VEGF，常见的药物有三种：Avastin、Lucentis、Eylea，还有一种为长效型类固醇Ozurdex ...

Bs: Bevasiranib sodium; CABERNET: A study of Strontium 90 β Radiation With Lucentis to Treat Age-Related Macular Degeneration; CARBON: Combination of Bevasiranib and Lucentis Therapy in Wet AMD ...

"I am thrilled to further strengthen and enrich Ocular's senior leadership team with the appointment of Namrata as Chief ...

如心衰爆款药物Entresto（60亿美元）、IL-17A单抗Cosentyx（50亿美元）、IgE单抗Xolair（36亿美元），Revolade、Kesimpta、Kisqali、Lucentis、Tafinlar、Tasigna的营收 ...

Opthea is a clinical-stage biotech firm developing Sozinibercept, targeting VEGF-C and VEGF-D for wet AMD, with Phase 3 ...

Regeneron should weather the Eylea biosimilar launch storm and continue to deliver long-term shareholder value. See why REGN ...

The products—ReoPro, Lucentis and Cimzia—are used as treatments for cardiovascular, ophthalmic and immunological indications, respectively (Table 1). All three approved products are Fab molecules.